Adalimumab - An effective and promising treatment for patients with fistulizing Crohn's disease: A case series

被引：7

作者：

Kouklakis G. ^{[1
]}

Efremidou E.I. ^{[1
]}

Zezos P. ^{[1
]}

Liratzopoulos N. ^{[1
]}

Souftas V.D. ^{[2
]}

Gatopoulou A. ^{[1
]}

Simopoulos K. ^{[3
]}

Manolas K.J. ^{[1
]}

机构：

[1] First Surgical Department, Democritus University of Thrace, University Hospital of Alexandroupolis

[2] Department of Radiology, Democritus University of Thrace, University Hospital of Alexandroupolis, Dragana 681 00, Alexandroupolis

[3] Second Surgical Department, Democritus University of Thrace, University Hospital of Alexandroupolis, Dragana 681 00, Alexandroupolis

来源：

Journal of Medical Case Reports | / 5卷 / 1期

关键词：

Infliximab; Adalimumab; Spontaneous Closure; Fistula Closure; Adalimumab Treatment;

D O I：

10.1186/1752-1947-5-109

中图分类号：

学科分类号：

摘要：

Introduction. Crohn's disease is a chronic inflammatory bowel disease of unknown etiology which may affect any part of the bowel. Fistulas are a common and often serious complication of Crohn's disease. The treatment for fistulizing Crohn's disease can be medical, surgical or a combination of the two. Recently, adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, has been suggested as a safe and effective treatment for the induction and maintenance of remission in adult patients with moderate to severe Crohn's disease, who are refractory to conventional therapy or intolerant to infliximab. However, large studies focusing on evaluating the efficacy of adalimumab in fistulizing Crohn's disease have not yet been published. Case presentation. We report the cases of three patients, of European Caucasian ethnicity and Greek nationality, with active luminal and fistulizing Crohn's disease. All of the cases were treated successfully with adalimumab. Patient 1 (a 44-year-old man) and patient 2 (an 18-year-old woman) developed early post-surgical enterocutaneous fistulas, while patient 3 (a 20-year-old woman) had peri-anal fistulizing Crohn's disease. Adalimumab treatment (160 mg subcutaneously at week zero, 80 mg at week two, and 40 mg every other week) was used for three different indications: (1) after the failure of other conservative medical treatments for Crohn's disease (patient 1); (2) as a monotherapy in treating a naive patient (patient 2); (3) after an intolerance to infliximab (patient 3). A remission of the active luminal and fistulizing disease was achieved soon after the initiation of adalimumab and sustained thereafter with maintenance doses. No further surgical intervention was required and no adverse effects were observed in any of the cases. Conclusions: Fistulizing Crohn's disease remains a challenge in clinical practice. Adalimumab seems to be an effective, well-tolerated and safe treatment option for the induction and maintenance of remission in patients with moderate to severe peri-anal fistulizing Crohn's disease. Furthermore, adalimumab seems to be a promising treatment option for patients with moderate to severe fistulizing Crohn's disease with enterocutaneous fistulas. However, this clinical observation needs to be investigated in further clinical trials. © 2011 Kouklakis et al; licensee BioMed Central Ltd.

引用

共 15 条

[1]

Schwartz D.A., Loftus Jr. E.V., Tremaine W.J., Panaccione R., Harmsen W.Scott, Zinsmeister A.R., Sandborn W.J., The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota, Gastroenterology, 122, 4, pp. 875-880, (2002)

[2]

Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., Kamm M.A., Korzenik J.R., Lashner B.A., Onken J.E., Rachmilewitz D., Rutgeerts P., Wild G., Wolf D.C., Marsters P.A., Travers S.B., Blank M.A., Van Deventer S.J., Infliximab maintenance therapy for fistulizing crohn's disease, New England Journal of Medicine, 350, 9, pp. 876-885, (2004)

[3]

Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., Panaccione R., Wolf D., Pollack P., Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial, Gastroenterology, 130, pp. 323-333, (2006)

[4]

Colombel J., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J.D., Pollack P.F., Adalimumab for maintenance of clinical response and remission in patients with crohn's disease: The CHARM trial, Gastroenterology, 132, 1, pp. 52-65, (2007)

[5]

Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lulcas M., MacIntosh D.G., Panaccione R., Wolf D., Kent J.D., Bittle B., Li J., Pollack P.F., Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial, Gut, 56, 9, pp. 1232-1239, (2007)

[6]

Hinojosa J., Gomollon F., Garcia S., Bastida G., Cabriada J.L., Saro C., Ceballos D., Penate M., Gassull M.A., Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: A prospective, open-label, multicentre trial, Alimentary Pharmacology and Therapeutics, 25, 4, pp. 409-418, (2007)

[7]

Colombel J.F., Schwartz D.A., Sandborn W.J., Kamm M.A., D'Haens G., Rutgeerts P., Enns R., Panaccione R., Schreiber S., Li J., Kent J.D., Lomax K.G., Pollack P.F., Adalimumab for the treatment of fistulas in patients with Crohn's disease, Gut, 58, pp. 940-948, (2009)

[8]

Peyrin-Biroulet L., Deltenre P., De Suray N., Branche J., Sandborn W.J., Colombel J., Efficacy and safety of tumor necrosis factor antagonists in crohn's disease: Meta-analysis of placebo-controlled trials, Clinical Gastroenterology and Hepatology, 6, 6, pp. 644-653, (2008)

[9]

Hadziselimovic F., Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease, Journal of Pediatric Gastroenterology and Nutrition, 46, 2, pp. 208-211, (2008)

[10]

Taner T., Cima R.R., Larson D.W., Dozois E.J., Pemberton J.H., Wolff B.G., Surgical treatment of complex enterocutaneous fistulas in IBD patients using human acellular dermal matrix, Inflamm Bowel Dis, 15, 8, pp. 1208-1212, (2009)

← 1 2 →